Interferons and other cytokines in head and neck cancer.
The use of cytokines in head and neck cancer is increasingly under investigation. Clinical trials have tested the interferons, interleukin-2 and other cytokines as single agents and in various combinations. The addition of interferon to the cisplatin and 5-fluorouracil (5-FU) regimens (with and without leucovorin) has been explored. A randomized international trial comparing cisplatin and 5-FU with cisplatin, 5-FU and interferon-alpha 2b is in progress.
Hamasaki
V K
VK
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Vokes
E E
EE
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016207:Cytokines; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons